![](https://s43720.pcdn.co/wp-content/uploads/2022/09/mushroom-lab.jpg)
Revive Therapeutics sees hope in nerve agent tests
The company indicated that early test results are expected in August. Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV) released an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with …